December 5, 2025
UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance
UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships
Crescent Biopharma and Kelun-Biotech Announce Reciprocal Licensing Pact for PD-1xVEGF and ADC Cancer Therapies
Crescent Biopharma; Kelun-Biotech; PD-1xVEGF; CR-001; SKB105; reciprocal licensing; oncology partnership; China; ADC; bispecific antibody